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a Psoriasis Patient Support Group (APLCP). The CES-D,
a short self-report scale composed of 20 items, is a ques-
tionnaire designed to measure DS in the general popula-
tion. The CES-D is widely used in epidemiological surveys
on large populations. The PDI is a questionnaire speciﬁc
for psoriasis patients. RESULTS: Two hundred ninety-
seven questionnaires were returned (June 2002): response
rate 39.6%. The sex ratio Men(M)/Women(W) was
47/53. Mean age: 48.8 years. Mean age of diagnosis: 26.3
years. The average to the total PDI score was 10.3 (sd:
7.7 rank 0 to 39) i.e 22.8 (sd: 17.10) when reported to a
scale of 0 to 100. Signiﬁcant difference was observed
between W and M for the global handicap score 24.53
vs 19.87 p < 0.02. Two groups were identiﬁed: ﬂare-up
of psoriasis (49.5%), psoriasis not in ﬂare-up (48%)—no
answers (2.5%)—Psoriasis had a greater affect on
patients with episode: PDI score = 24.9 (sd: 17.02) than
patient without episode: PDI score = 20.27 (sd: 16.91)
This difference was signiﬁcant (p < 0.05). In the studied
population, 44.6% of the patients reported DS (CES-D+)
whereas 55.4% did not (CES-D-). In CES-D+ patients the
PDI score = 30.98 (sd: 18.28) was higher than the score
in CES-D-patients: PDI-score = 16.43 (sd: 13.97). This
difference was signiﬁcant (p < 2.10–11). CONCLUSION:
Patients in a current ﬂare-up of psoriasis are more
affected and feel more disabled in their daily life (higher
disability score and higher frequency of DS) compared to
patients without episode. Patients with DS (CES-D+),
reported an higher impact of their psoriasis on their
quality of life (PDI score 30.98 versus 16.43).
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OBJECTIVES: Studies show that 43% of all adults suffer
adverse health effects from stress. Stress is linked to six
of the leading causes of death. Results of the Brief Hassles
study showed that younger people deal with hassles
(stress) in different ways than older adults. While daily
hassles tended to really upset those aged 25 to 39,
“boomer” types aged 40 to 59 were more likely to shrug
them off. This has prompted increased interest in how
speciﬁc age groups handle stress. Therefore, the objectives
of this study are to determine the top three stressors for
college students and to explore how different demo-
graphics (race, age, gender, classiﬁcation, and income)
affect those stressors. METHODS: Items for the ques-
tionnaire were obtained from the Brief College Student
Hassles Scale (BCSHS), Erindale College University of
Toronto. Students responded to a Likert-type scale that
ranged from 1 (never) to 5 (extremely often) and ranked
stressors in terms of frequency and the extent to which
they were bothered by the stressor. The sample consisted
of 122 students in pharmacy school at Florida A & 
M University. Means, correlation, and regression were
conducted using SPSS. RESULTS: The top three stressors
for college students were parking problems, exams, and
schoolwork. Demographics had a signiﬁcant affect on
stressors (p < .05). Results of the regression analysis
showed that for females income was a good predictor of
the variation in parking problems (p = .042) and that for
males age was a good predictor of the variation in exams
(p = .006). There was a positive relationship shown
between gender and weight/dietary management (p =
.007). There was a negative relationship shown between
age and appearance of self (p = .021). CONCLUSIONS:
There is a connection between demographics and stress.
Through increased awareness the University’s Counseling
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OBJECTIVE: The purpose of this study was to evaluate
the implementation stage of the innovation-decision
process by observing the adoption of new asthma treat-
ment guidelines (1997) in a social system, i.e. recipients
of the Idaho Medicaid program. METHODS: Paid claims
for inpatient, outpatient and pharmacy services during
the period of 1994 through 2000 were collected. To be
included in the study, the patient must have received at
least one prescription for an inhaled b2-agonists. Since
the therapy guidelines for patients under the age of ﬁve
years are slightly different they were excluded from the
study. Patients classiﬁed under Chronic Obstructive Pul-
monary Disorder (COPD) were excluded from this study.
Chi-Square test was used to observe statistical difference
for categorical variables. Level of signiﬁcance was
adjusted with the Bonferroni method to avoid the possi-
bility of rejecting the null by chance alone. RESULTS: A
total of 14,458 unique patients met the inclusion criteria.
Percent of patients on appropriate therapy (using more
than 4 short acting inhaler in 3 months or any long acting
inhaler AND using anti-inﬂammatory medications)
increased from 52.8% in 1994 to 69.2% in the year
2000. Chi-square analysis revealed a signiﬁcant relation-
ship between year and whether or not a patient was on
appropriate therapy (c2 value = 227.582, p < 0.001). The
percentage of male patients on appropriate therapy
increased from 57% in 1994 to approximately 75% in
the year 2000, for female patients on appropriate therapy
increased from almost 50% in 1994 to 66% in the year
2000 (Bonferroni adjusted p-values for each year <0.007).
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CONCLUSIONS: The new treatment guidelines were
implemented on more patients by year 2000. More males
were found to be on appropriate therapy than females.
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OBJECTIVES: Randomized clinical trials (RCTs) are the
gold standard for determining efﬁcacy of pharmaceutical
treatments, but ﬁndings from RCTs are often difﬁcult 
to translate into real-world (non-randomized) environ-
ments. This observational registry was designed to iden-
tify real-world outcomes among asthma patients receiving
various treatments for asthma. The registry protocol mir-
rored a previous RCT and was designed to provide con-
ﬁrmatory evidence for generalizability of prior research
ﬁndings. METHODS: Four hundred eighty-four physi-
cians from 13 states, including the west, central, north-
eastern, southeastern and midwestern areas of the U.S.,
were recruited and trained in registry procedures. Patients
were eligible if they were 15 years or older and required
a change in asthma control therapy as determined by their
physician during a regularly scheduled ofﬁce visit. No
recruitment was allowed to protect the observational
status of the registry. Asthma Control Questionnaire
(ACQ), Asthma Quality of Life Questionnaire (AQLQ),
medication satisfaction, and productivity end point data
have been obtained from baseline and will be obtained
from 1-month, 3-month, 6-month and 1-year surveys.
Utilization and cost data for inpatient, outpatient, emer-
gency room, and prescriptions will be obtained from the
individual’s health insurance claims data. RESULTS:
Eighty-one percent of physicians were general internists,
and 19% were allergists or pulmonologists. Sixty-seven
percent of all physicians had no previous research expe-
rience. Over 1400 patients entered the registry during the
enrollment period (01/2002–12/2002). Baseline charac-
teristics were well balanced across the four cohorts
despite lack of randomization. Analysis of baseline self-
reported ACQ and AQLQ individual questions identiﬁed
no statistically signiﬁcant differences between cohorts.
Follow-up survey results will be reported in future analy-
ses. CONCLUSIONS: Non randomized registry studies
can complement RCTs by providing an ample well bal-
anced sample size that is representative of real-word prac-
tice and makes available rapid feedback on clinical and
economic outcomes.
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OBJECTIVES: Randomised controlled clinical trials
demonstrate how well treatments work under ideal con-
ditions (clinical efﬁcacy). However, once efﬁcacy has been
established there is a need to show how well treatment
work in the less ideal conditions of normal clinical prac-
tice (clinical effectiveness). This study is the ﬁrst to
demonstrate the clinical effectiveness of budesonide/for-
moterol in a single inhaler in the treatment of asthma in
UK general practice. METHODS: Patients with inade-
quately controlled asthma were identiﬁed following a
review of their patient notes and a consultation with a
clinical nurse specialist using criteria agreed with the
general practitioner. These patients were referred to the
doctor for a treatment review and a subsequent assess-
ment at six months. RESULTS: As a result of the review
119 patients, previously treated with ≥200mcg inhaled
corticosteroid daily, received budesonide/formoterol
(80/4.5mcg or 160/4.5mcg 1–2 puffs twice daily) in a
single inhaler for the ﬁrst time. Improvements were
observed in all measures of health outcomes. There was
a signiﬁcant increase in the mean peak expiratory ﬂow
between initial (415L/min) and 6 month (447L/min)
assessments (p < 0.0001). Patients reported a greater pro-
portion of symptom-free days (p < 0.0001) fewer episodes
of symptoms in the day (p < 0.0001) and at night (p <
0.0001). They reported a reduced use of reliever medica-
tion (p < 0.0001) and a reduction of exercise induced
asthma (p < 0.0001). There was a signiﬁcant decrease in
routine asthma-related primary care consultations (p <
0.0005) and fewer emergency GP visits (p < 0.001).
Patients understood their treatment better (p < 0.0001),
were concerned about their asthma for less of the time 
(p < 0.0001), and 98% of patients felt they had beneﬁted
from taking part in the programme of which this change
in therapy was a part. CONCLUSIONS: In this group of
asthmatic patients, inadequately controlled on ≥200mcg
inhaled corticosteroid daily, budesonide/formoterol in a
single inhaler provided signiﬁcant improvements, which
demonstrate superior clinical effectiveness.
